OBJECTIVE: To explore the clinical characteristics and mechanism of adverse drug reactions of hypertension complicated with proteinuria during the treatment of advanced malignant tumor with anlotinib

so as to provide reference for safe and rational drug use. METHODS: Patients with advanced malignant tumor treated with anlotinib in People’s Hospital of Shandong Guangrao County from Jun. 2018 to Jul. 2020 were collected. Clinical pharmacists participated into the monitoring

evaluation and analysis of adverse drug reactions of hypertension complicated with proteinuria induced by anlotinib

assisted clinicians to adjust the dosage of antihypertensive drugs and antihypertensive therapy. RESULTS: A total of 123 patients with advanced malignant tumor treated with anlotinib were included

of which 6 patients developed adverse drug reactions of hypertension complicated with proteinuria

with the incidence of 4. 88%. During the treatment period

the clinical pharmacist provided pharmacological monitoring and developed individualized medication regimens. Ultimately

all patients’ blood pressure was well controlled and urine protein returned to negative

which ensured the continuity of anti-tumor therapy. CONCLUSIONS: Clinical pharmacists should master the relevant theories of new anti-tumor drugs

actively carry out pharmaceutical care

participate into the optimization of clinical treatment regimens

improve the level of drug therapy

and promote the safety and rationality of clinical drug use.